AR positive

Discover the complexities of PSMA heterogeneity and regulation in metastatic #ProstateCancer with AR-positive and AR-negative phenotypes in this insightful discussion with @mishabeltran @DanaFarber and @AndreaMiyahira @PCFnews. #WatchNow on UroToday > https://t.co/pSgn6fDbJ3 (@urotoday)

Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer @mishabeltran @NatureCancer #AACR2023 #AACR23 https://t.co/zbDct5XS4K (@imedverse)

💫ONLINE NOW @NatureCancer “Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer” by @mishabeltran @mkbakht & Co. @NatResCancer Read it here👇 https://t.co/xrn1NekyVD https://t.co/Nmu0c54fjm (@NatureCancer)

Couldn’t be prouder of the amazing work of ⁦@mkbakht⁩ dissecting the landscape of PSMA heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Congratulations ⁦@mishabeltran⁩! ⁦@L_Porterlabrats⁩ https://t.co/OKBKsaO3Lh (@LisaPorter2)

Congrats ⁦⁦@mishabeltran⁩ and team. Very nice work! Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer | Nature Cancer https://t.co/JilBPgP7zO (@AAytesLab)

So excited to share our new paper @NatureCancer on PSMA regulation in AR-positive and AR-negative prostate cancer. Congratulations to lead author @mkbakht @DanaFarber We are grateful for many wonderful collaborators @DanaFarber_GU @PCF_Science https://t.co/SwdSVhnAx3 (@mishabeltran)

Outstanding work from @mishabeltran Lab and colleagues in @NatureCancer==> "Landscape of Prostate-Specific Membrane Antigen Heterogeneity and Regulation in AR-positive and AR-negative Metastatic Prostate Cancer" https://t.co/Fj31BHlFa7 @DanaFarber_GU @DanaFarber @OncoAlert https://t.co/zTQY5yyHjh (@DrChoueiri)

Important work from ⁦@mishabeltran⁩ ⁦@DanaFarber_GU⁩ Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer | Nature Cancer https://t.co/BRaBwa0KGF (@EllisLab_)

TNBC, MBC, progressed on all standard first line (AC, P-C)drugs. What is the best option in this case? Any role of CDK4/6i based on preliminary data along with PI3Ka targeting? This pt is AR positive, too (@pradeepbab)

RARE corner. What is it? Looks like ductal breast cancer under the microscope. Skin mets are unusual. May have PI3K pathway alterations as well as androgen receptor and Her2 positivity. These two men showed remarkable response to mTOR inhibitor based therapy (@Dr_R_Kurzrock)

We're thrilled to share results of a clinical trial led by @AlanHoMDPhD for people with androgen receptor-positive salivary #glandcancer. @AndrewChowMDPhD and @charlesrudin explore novel predictors of immunotherapy effectiveness against #lungcancer. ⬇️ https://t.co/YcV0Svntp2 (@MSK_DeptOfMed)

#SABCS2022 #bcsm so proud of my superstar mentee Hannah Krause sharing her work investigating mechanisms of ARSI resistance in AR positive TNBC @oreganruth @JoshLangMD @uw_hemeoncpc (@marina_sharifi)

AR-positive subset of TNBC is definable. But to date, not clinically actionable. Perhaps as @shomgoel suggests, drugs active in luminal tumors (i.e. CDK4/6i) will have a role ?? (@DrHBurstein)

Enobosarm, an investigational, nonsteroidal, selective androgen receptor agonist, could represent a new treatment approach in estrogen receptor–positive, AR-positive metastatic breast cancer @breastoncdoc @UPMCHillmanCC #bcsm https://t.co/RLFz4alDLQ (@OncLive)

Would you like hear Dr Hope Rugo @hoperugo @UCSF speak about novel treatments for TNBC like a new antibody drug conjugate, lovingly known as "sassy." Do you know what a SARM is? It is a special class of drugs for Androgen Receptor (AR) positive BC. Listen and find out. (@ourmbclife)

I wonder similar concept applies to androgen receptor-positive breast cancer. (@teamoncology)